MS patients treated with ocrelizumab, rituximab, or fingolimod showed a reduced immune response after SARS-CoV-2 mRNA vaccination.
[11C]flumazenil (FMZ) positron emission tomography (PET) demonstrated higher GABA-receptor binding for cognitively preserved (CP) MS patients.
Evobrutinib significantly reduced MRI activity and patient numbers with qualified MS relapses regardless of baseline blood neurofilament light chain levels.
A newly developed dynamic scoring system can be used to support the decision whether or not to switch at an early stage from first- to second-line therapy.
The number of cortical lesions at MS diagnosis accurately discriminates between the presence of absence of cognitive impairment after 20 years.
In a population-based MS cohort, COVID-19 severity and mortality was found to depend on age, comorbidity, and degree of disability.
In both real-world and clinical trial setting, MRI activity is a more sensitive tool to measure disease activity than relapses in secondary progressive MS.
Personality traits that are often seen in patients with a recent MS diagnosis less than 2 years ago are, first and foremost, being highly agreeable, followed by being conscientious, open, and neurotic.
In a comparative analysis of common initial MS therapies among Swedish MS patients, rituximab demonstrated the lowest risk of relapses and MRI lesions.
A high-sensitive technique to detect antibodies to lipids in MS patients was developed. Analysis showd IgM-PC as the most sensitive MS biomarker so far[1].
Sustained efficacy was observed for aquaporin-4-IgG-seropositive (AQP4-IgG+) NMOSD in the open-label extension period of a Phase 3 study.
Presence and number of cortical lesions at MS diagnosis predicted development of secondary progressive MS and disability accumulation in a 20-year study.
Preliminary trial data showed that the drug was generally well tolerated and drove sustained disability improvement in a significant proportion of patients [1].
A randomised double-blind controlled pilot trial demonstrated patient benefits of melatonin in MS patients. Sleep disturbances and fatigue may be alleviated by this supplement.
Bio-naïve and bio-experienced patients with moderately to severely active UC achieved more clinical remission when treated with filgotinib over placebo at weeks 10 and 58.
Upadacitinib outperformed placebo at all primary and secondary endpoints evaluating maintenance therapy for patients with moderately to severely active ulcerative colitis.
Clinical remission was sustained throughout the 52-week FORTIFY maintenance study for patients with Crohn’s Disease who responded well to risankizumab induction therapy.
Ethnic or religion-based forms of discrimination against trained medical specialists and the influence of National Socialism in neurology were topics of focus at the DGN 2021.
A treat-to-target strategy of ustekinumab in CD patients could maintain a proportion of patients in endoscopic response in a long-term extension of a phase 3 trial.
The ASTIClite trial, developed to analyse the efficacy of haematopoietic stem cell transplantation on refractory Crohn’s disease patients, was halted due to unexpected serious events.